Gastrointestinal cancers are a group of highly aggressive malignancies, and novel therapeutic strategies with higher clinical efficacy are being actively sought. ‘Immunotherapy’ is now emerging as one such promising strategy for the treatment of these tumors. This article briefly reviews the recent advances that utilize targeting of immune checkpoint pathways, in the management of gastrointestinal malignancies
Gastrointestinal (GI) malignancies (esophageal, gastric, pancreatic, intra- and extra-biliary ductal...
Immune checkpoints blockade (ICB) has made revolutionary progress in cancer therapy recently. The de...
Background: Gastroesophageal cancers (GECs) carry considerable morbidity and mortality, and demonstr...
Gastrointestinal cancers are a group of highly aggressive malignancies, and novel therapeutic strate...
Gastrointestinal cancers are a group of highly aggressive malignancies, and novel therapeutic strate...
Gastrointestinal cancers are a group of highly aggressive malignancies, and novel therapeutic strate...
Immunotherapy is a rapidly evolving treatment paradigm that holds promise to provide long-lasting su...
Abstract Gastrointestinal (GI) cancers are a group of highly aggressive malignancies with a huge dis...
The new therapeutic approach of using immune checkpoint inhibitors as anticancer agents is a landmar...
Gastrointestinal (GI) cancer constitutes a highly lethal entity among malignancies in the last decad...
Gastrointestinal cancer is a leading cause of cancer-related mortality and remains a major challenge...
The new therapeutic approach of using immune checkpoint inhibitors as anticancer agents is a landmar...
Gastrointestinal (GI) cancers are a group of highly aggressive malignancies with a huge disease burd...
Noncolorectal gastrointestinal (GI) malignancies are among the most frequently diagnosed cancers. De...
In the last few years, the unprecedented results of immune checkpoint inhibitors have led to a parad...
Gastrointestinal (GI) malignancies (esophageal, gastric, pancreatic, intra- and extra-biliary ductal...
Immune checkpoints blockade (ICB) has made revolutionary progress in cancer therapy recently. The de...
Background: Gastroesophageal cancers (GECs) carry considerable morbidity and mortality, and demonstr...
Gastrointestinal cancers are a group of highly aggressive malignancies, and novel therapeutic strate...
Gastrointestinal cancers are a group of highly aggressive malignancies, and novel therapeutic strate...
Gastrointestinal cancers are a group of highly aggressive malignancies, and novel therapeutic strate...
Immunotherapy is a rapidly evolving treatment paradigm that holds promise to provide long-lasting su...
Abstract Gastrointestinal (GI) cancers are a group of highly aggressive malignancies with a huge dis...
The new therapeutic approach of using immune checkpoint inhibitors as anticancer agents is a landmar...
Gastrointestinal (GI) cancer constitutes a highly lethal entity among malignancies in the last decad...
Gastrointestinal cancer is a leading cause of cancer-related mortality and remains a major challenge...
The new therapeutic approach of using immune checkpoint inhibitors as anticancer agents is a landmar...
Gastrointestinal (GI) cancers are a group of highly aggressive malignancies with a huge disease burd...
Noncolorectal gastrointestinal (GI) malignancies are among the most frequently diagnosed cancers. De...
In the last few years, the unprecedented results of immune checkpoint inhibitors have led to a parad...
Gastrointestinal (GI) malignancies (esophageal, gastric, pancreatic, intra- and extra-biliary ductal...
Immune checkpoints blockade (ICB) has made revolutionary progress in cancer therapy recently. The de...
Background: Gastroesophageal cancers (GECs) carry considerable morbidity and mortality, and demonstr...